schizophrenia disorders Clinical Research Trials

Found 404 clinical trials

featured

Schizophrenia Relapse Prevention

This study tests whether the investigational drug prevents patients with schizophrenia from becoming worse. This study looks at how well patients tolerate the investigational drug and how

50 views
23 Nov, 2020
1 location

featured

Study Seeking Patients with Schizophrenia

0 views
07 Nov, 2020
6 locations

featured

Treatment of Adolescents With Schizophrenia

This study is being conducted to determine the safety & efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.

36 views
23 Nov, 2020
1 location

featured

Schizophrenia with Changes in Thinking Skills

Local study doctors are conducting this clinical research study to learn more about an oral investigational drug that is taken with your current schizophrenia medication. They want to evaluate the

77 views
23 Nov, 2020
1 location

featured

Add-On Treatment for Schizophrenia Symptom Management

schizophrenia in adults, when added to your current schizophrenia treatment.

42 views
23 Nov, 2020
1 location

featured

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia.

schizophrenia on stable antipsychotic treatment.

19 views
23 Nov, 2020
1 location

featured

A multicenter, randomized, double-blind, placebo-controlled, parallel-arm study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of negative symptoms of schizophrenia

The purpose of this research is to evaluate the efficacy, safety and tolerability of AVP-786 compared to placebo for the treatment of negative symptoms of schizophrenia. Negative symptoms of

0 views
05 Apr, 2021
1 location

featured

A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects with Schizophrenia Treated Prospectively for 6-months with Abilify MyCite®

To compare inpatient psychiatric hospitalization rates (proportion of subjects with ≥ 1 inpatient psychiatric hospitalizations) between the retrospective period (Months 1 to 3) while subjects are on oral standard-of-care antipsychotic treatment and the prospective period (Months 1 to 3) after the subjects switch to Abilify MyCite®.